Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 614,947
  • Shares Outstanding, K 52,967
  • Annual Sales, $ 8,780 K
  • Annual Income, $ -104,700 K
  • EBIT $ -117 M
  • EBITDA $ -115 M
  • 60-Month Beta 0.95
  • Price/Sales 70.46
  • Price/Cash Flow N/A
  • Price/Book 2.65

Options Overview Details

View History
  • Implied Volatility 139.37% ( +4.20%)
  • Historical Volatility 70.21%
  • IV Percentile 91%
  • IV Rank 53.76%
  • IV High 228.10% on 01/22/24
  • IV Low 36.18% on 08/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 146
  • Volume Avg (30-Day) 176
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 4,424
  • Open Int (30-Day) 4,710

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.51
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.61 +6.69%
on 12/19/24
14.39 -21.31%
on 12/10/24
-0.11 (-0.96%)
since 11/22/24
3-Month
10.61 +6.69%
on 12/19/24
14.72 -23.10%
on 11/14/24
-1.54 (-11.98%)
since 09/24/24
52-Week
4.09 +176.77%
on 02/13/24
17.58 -35.61%
on 06/13/24
+5.99 (+112.38%)
since 12/22/23

Most Recent Stories

More News
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...

CDXC : 5.44 (+2.64%)
ADMA : 17.41 (-1.75%)
TARS : 54.04 (-0.68%)
STOK : 11.32 (-2.50%)
Insider Sale: CEO of $STOK (STOK) Sells 6,786 Shares

Edward M. MD Kaye, the CEO of $STOK ($STOK), sold 6,786 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.9% of their shares....

STOK : 11.32 (-2.50%)
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares

Barry Ticho, the CHIEF MEDICAL OFFICER of $STOK ($STOK), sold 13,945 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 22.8%...

STOK : 11.32 (-2.50%)
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome, a severe...

IMCR : 28.66 (+1.85%)
CSTL : 27.72 (+0.87%)
STOK : 11.32 (-2.50%)
SPRO : 0.9375 (+1.59%)
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 10,000 Shares

Barry Ticho, the CHIEF MEDICAL OFFICER of $STOK ($STOK), sold 10,000 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 16.3%...

STOK : 11.32 (-2.50%)
Stocks Inch Higher After February's US Durable Goods Orders Released

Stocks are slightly up this morning as market participants reacted to February's US Durable Goods Report.

$SPX : 6,040.04 (+1.10%)
SPY : 601.30 (+1.11%)
$DOWI : 43,297.03 (+0.91%)
DIA : 432.50 (+0.84%)
$IUXX : 21,797.65 (+1.37%)
QQQ : 529.96 (+1.36%)
TTWO : 185.39 (+1.18%)
UAL : 101.16 (+1.69%)
MCD : 293.99 (+0.93%)
DIS : 112.56 (+1.04%)
OCDO.LN : 312.700 (+0.74%)
STOK : 11.32 (-2.50%)
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street

This small-cap biotech might be a hidden gem.

ACAD : 17.07 (-0.58%)
STOK : 11.32 (-2.50%)
Why Shares of Stoke Therapeutics Plummeted Tuesday

The company's shares fell after it released early trial results on its lead therapy.

STOK : 11.32 (-2.50%)
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported...

STOK : 11.32 (-2.50%)
Stoke Therapeutics to Present at the BofA Securities Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 11.32 (-2.50%)

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 12.10
2nd Resistance Point 11.85
1st Resistance Point 11.59
Last Price 11.32
1st Support Level 11.08
2nd Support Level 10.83
3rd Support Level 10.57

See More

52-Week High 17.58
Fibonacci 61.8% 12.43
Last Price 11.32
Fibonacci 50% 10.84
Fibonacci 38.2% 9.24
52-Week Low 4.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar